Amrutanjan Health Care Limited has informed the Exchange that Board of Directors at its meeting held on May 15, 2025, recommended Final Dividend of 2.60 per equity share.
AMRUTANJAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.0 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Amrutanjan Health Care's board, at its May 15, 2025 meeting, approved audited FY25 results and recommended a final dividend of Rs. 2.60 per share on 2.89 crore equity shares, taking the total FY25 dividend to Rs. 3.60 per share (including Rs. 1 interim already paid). For FY25, revenue from operations rose about 7.3% to Rs. 451.82 crore, while profit after tax grew roughly 13% to Rs. 50.83 crore, with basic EPS at Rs. 17.58 versus Rs. 15.50 last year. Q4 FY25 revenue was Rs. 135.41 crore and PAT was Rs. 15.18 crore, both up year-on-year. The statutory auditor B S R & Co. LLP issued an unmodified opinion, and the company also announced the retirement of Company Secretary Mr. M Srinivasan on May 31, 2025, with Mr. Gagan Preet Singh taking over from June 1, 2025.
The final dividend reinforces a consistent shareholder return story, and the steady single-digit revenue growth with a low double-digit profit rise signals stable operating performance. The clean audit opinion and routine key managerial personnel change are neutral to mildly positive, with no red flags for shareholders.